Were Analysts Bearish Medidata Solutions, Inc. (NASDAQ:MDSO) This Week?

Medidata Solutions, Inc. (NASDAQ:MDSO) LogoInvestors sentiment increased to 1.38 in 2018 Q2. Its up 0.43, from 0.95 in 2018Q1. It improved, as 22 investors sold Medidata Solutions, Inc. shares while 65 reduced holdings. 40 funds opened positions while 80 raised stakes. 63.19 million shares or 1.50% more from 62.26 million shares in 2018Q1 were reported.
Principal Fincl Group Inc owns 261,168 shares for 0.02% of their portfolio. Employees Retirement Of Ohio holds 0.06% or 138,080 shares in its portfolio. Malaga Cove Ltd Co owns 36,530 shares for 1.49% of their portfolio. Rice Hall James Associate Ltd holds 0.36% in Medidata Solutions, Inc. (NASDAQ:MDSO) or 121,903 shares. Axiom Int Investors Ltd Llc De reported 0.19% in Medidata Solutions, Inc. (NASDAQ:MDSO). Invesco Ltd reported 0.03% of its portfolio in Medidata Solutions, Inc. (NASDAQ:MDSO). Gemmer Asset Mgmt Limited Co has invested 0% in Medidata Solutions, Inc. (NASDAQ:MDSO). South Dakota Inv Council holds 57,900 shares. Driehaus Mngmt Ltd Limited Liability Company, Illinois-based fund reported 32,574 shares. Cordasco, Pennsylvania-based fund reported 300 shares. Royal Bancorp Of Canada invested in 0.02% or 480,891 shares. Cornerstone Advsrs owns 15 shares. Fortaleza Asset Management Inc owns 2,195 shares. Schroder Invest Mngmt Grp has invested 0% in Medidata Solutions, Inc. (NASDAQ:MDSO). Stephens Invest Grp Incorporated Lc accumulated 817,760 shares or 1.3% of the stock.

Since May 21, 2018, it had 0 buys, and 8 insider sales for $4.89 million activity. 9,288 Medidata Solutions, Inc. (NASDAQ:MDSO) shares with value of $752,571 were sold by Otner Michael I.. SHAPIRO LEE sold 12,500 shares worth $952,000. Another trade for 3,000 shares valued at $226,560 was sold by Bergmann Rouven.

Medidata Solutions, Inc. (NASDAQ:MDSO) Ratings Coverage

Among 5 analysts covering Medidata Solutions (NASDAQ:MDSO), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Medidata Solutions had 8 analyst reports since May 21, 2018 according to SRatingsIntel. The company was maintained on Wednesday, June 13 by Deutsche Bank. The firm earned “Outperform” rating on Tuesday, July 17 by RBC Capital Markets. On Tuesday, June 12 the stock rating was maintained by Piper Jaffray with “Buy”. On Monday, May 21 the stock rating was downgraded by Morgan Stanley to “Equal-Weight”. Morgan Stanley maintained it with “Equal-Weight” rating and $84 target in Wednesday, July 25 report. As per Wednesday, May 23, the company rating was maintained by Piper Jaffray. Deutsche Bank maintained Medidata Solutions, Inc. (NASDAQ:MDSO) on Thursday, May 31 with “Buy” rating. Below is a list of Medidata Solutions, Inc. (NASDAQ:MDSO) latest ratings and price target changes.

25/07/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $79 New Target: $84 Maintain
17/07/2018 Broker: RBC Capital Markets Old Rating: Sector Perform New Rating: Outperform Old Target: $82 Upgrade
15/06/2018 Broker: First Analysis Rating: Equal-Weight New Target: $86 Initiates Coverage On
13/06/2018 Broker: Deutsche Bank Old Rating: Buy New Rating: Buy Old Target: $85 New Target: $90 Maintain
12/06/2018 Broker: Piper Jaffray Rating: Buy New Target: $98.0000 Maintain
31/05/2018 Broker: Deutsche Bank Rating: Buy New Target: $85.0000 Maintain
23/05/2018 Broker: Piper Jaffray Rating: Buy New Target: $98.0000 Maintain
21/05/2018 Broker: Morgan Stanley Old Rating: Overweight New Rating: Equal-Weight Old Target: $79 Downgrade

The stock decreased 1.71% or $1.2 during the last trading session, reaching $68.83. About 366,960 shares traded. Medidata Solutions, Inc. (NASDAQ:MDSO) has risen 7.57% since November 14, 2017 and is uptrending. It has underperformed by 8.05% the S&P500.

Medidata Solutions, Inc. provides cloud solutions for life sciences worldwide. The company has market cap of $4.21 billion. It offers Medidata Clinical Cloud that provides a software-as-a-service platform of technology and data analytics solutions to optimize activities across clinical development. It has a 81.07 P/E ratio. The companyÂ’s platform solutions includes Plan Study that addresses the areas to ensure optimal study design, grant development and negotiation, and investigator payments; and Support Sites, which provides robust risk management, reduced source document verification, real-time monitoring, on-time, accurate payments.

Another recent and important Medidata Solutions, Inc. (NASDAQ:MDSO) news was published by Seekingalpha.com which published an article titled: “Medidata Solutions, Inc. (MDSO) CEO Tarek Sherif on Q3 2018 Results – Earnings Call Transcript” on October 18, 2018.

Medidata Solutions, Inc. (NASDAQ:MDSO) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.